Simultaneous delivery of an RNP complex targeting the PD-L1 gene and the antitumor drug axitinib achieved PD-L1 knockout in cancer cells, significantly reduced immunosuppressive Tregs, and enhanced tumor growth inhibition 271. This evidence concerns the gene CD274 and cancer.